![Regenacy pharmaceuticals llc](/api/images/company-pic/0-2068840-company.jpg)
Kontaktiere uns
Über das Unternehmen
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Its compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with the first-in-class potential, currently positioned to enter Phase 2 clinical trials. Its investigation of ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function.
US
Unbekannt
Nicht verifiziertes Unternehmen
Geschäftstransparenz
- Firmeninfo nicht verifiziert
- Bitten Sie ihre Kunden um Bewertungen
- Auf negative Bewertungen wurde nicht geantwortet